#Uncoupling of proliferation and metastasis

[mestastop]

Understanding the Uncoupling of Proliferation and Metastasis 

The Uncoupling of Proliferation and Metastasis is a groundbreaking concept in cancer research that addresses how cancer cells can spread without uncontrolled growth. Mestastop provides innovative solutions to study and target this separation, helping in the development of therapies that specifically inhibit metastasis without affecting normal cell function. By understanding this mechanism, researchers can create more precise treatments to prevent cancer spread while minimizing side effects. Mestastop focuses on pioneering strategies to tackle metastasis as an independent factor, revolutionizing cancer treatment approaches. For more information, visit us at https://mestastop.com/, call us at +91 9177884450, or email us at bd@mestastop.com. Uncoupling of proliferation and metastasis

[naivelocus]

Current and upcoming mitochondrial targets for cancer therapy

Abstract

Mitochondria are essential intracellular organelles that regulate energy metabolism, cell death, and signaling pathways that are important for cell proliferation and differentiation. Therefore, mitochondria are fundamentally implicated in cancer biology, including initiation, growth, metastasis, relapse, and acquired drug resistance. Based on these implications, mitochondria have been proposed as a major therapeutic target for cancer treatment. In addition to classical view of mitochondria in cancer biology, recent studies found novel pathophysiological roles of mitochondria in cancer. In this review, we introduce recent concepts of mitochondrial roles in cancer biology including mitochondrial DNA mutation and epigenetic modulation, energy metabolism reprogramming, mitochondrial channels, involvement in metastasis and drug resistance, and cancer stem cells. We also discuss the role of mitochondria in emerging cancer therapeutic strategies, especially cancer immunotherapy and CRISPR-Cas9 system gene therapy.

Abbreviations

ETC, electron transport complexes;

ROS/RNS, reactive oxygen or nitrogen spices;

∆ψm, mitochondrial inner membrane potential;

TCA, TriCarboxylic Acid Cycle;

MPTP, mitochondrial permeability transition pore;

mtDNA, mitochondrial DNA;

ND5, NADH dehydrogenase 5;

mtDNMT1, mtDNA methyltransferase;

SAM, S-adenosyl-L-methionine;

IDH, Isocitrate dehydrogenase;

SDH, succinate dehydrogenase;

FH, fumarate hydratase;

GSH, glutathione;

HIF-1α, hypoxia-inducible transcription factor-1 α;

KEAP1, Kelch-like ECH-associated protein 1;

NRF2, nuclear farter (erythroid-derived 2)-like 2;

PDC, pyruvate dehydrogenase complex;

PDHE1α, PDC E1α subunit;

PDK1, 2, 3 and 4, pyruvate dehydrogenase kinase 1, 2, 3 or 4;

PDP1 and 2, pyruvate dehydrogenase phosphatases 1 or 2;

VDAC, voltage dependent anion channel;

ANT, adenine nucleotide translocator;

CypD, cyclophilin D;

MAC, mitochondrial apoptosis-induced channel;

mitoKv1.3, mitochondrial voltage-gated potassium channel;

MitoIKCa/KCa3.1, mitochondrial intermediated conductance calcium activated potassium channel;

BKCa/KCa1.1, large conductance calcium activated potassium channel;

SKCa/KCa3.1, small conductance calcium activated potassium channel;

mitoKATP, Mitochondrial ATP-sensitive potassium channel;

TASK-3, TWIK-related Acid-sensitive K+ channel-3;

KCNK9 UCP, uncoupling proteins;

MCU, Mitochondria Ca2+ uniporter;

TNBC, triple-negative breast cancer;

Mrs2, mitochondrial Mg2 + channel;

TOM/TIM, translocase of outer/inner membrane;

PGC1-α, peroxisome proliferator-activated receptor gamma, coactivator 1 alpha;

CSC, cancer stem cell;

PRX3, peroxiredoxin 3;

PD-1, programmed death-1;

CTLA-4, cytotoxic T lymphocyte antigen 4;

LAG-3, lymphocyte activation gene 3;

Tim-3, T cell immunoglobulin and mucin-containing gene 3;

CRISPR–Cas9, clustered regularly interspaced short palindromic repeats–CRISPR-associated 9;

CLIC4, chloride intracellular channel 4

Keywords

mitochondria;

mitochondria channels;

cancer stem cell;

cancer immunotherapy;

CRISPR-Cas9

Corresponding author at: National Research Laboratory for Mitochondrial Signaling, Department of Physiology, Cardiovascular and Metabolic Disease Center, College of Medicine, Inje University, Bokji-ro 75, Busanjin-gu, Busan 47392, Republic of Korea.

© 2017 Published by Elsevier Ltd.

Note to users: Accepted manuscripts are Articles in Press that have been peer reviewed and accepted for publication by the Editorial Board of this publication. They have not yet been copy edited and/or formatted in the publication house style, and may not yet have the full ScienceDirect functionality, e.g., supplementary files may still need to be added, links to references may not resolve yet etc. The text could still change before final publication.

Although accepted manuscripts do not have all bibliographic details available yet, they can already be cited using the year of online publication and the DOI, as follows: author(s), article title, Publication (year), DOI. Please consult the journal's reference style for the exact appearance of these elements, abbreviation of journal names and use of punctuation.

When the final article is assigned to volumes/issues of the Publication, the Article in Press version will be removed and the final version will appear in the associated published volumes/issues of the Publication. The date the article was first made available online will be carried over.

Author : Hyoung Kyu Kim, Yeon Hee Noh, Bernd Nilius, Kyung Soo Ko, Byoung Doo Rhee, Nari Kim, Jin Han

— Seminars in Cancer Biology

[mestastop]

Uncoupling of Proliferation and Metastasis: A New Frontier in Cancer Research

Cancer has long been associated with uncontrolled cell proliferation and metastasis—two intertwined processes that contribute to the complexity and lethality of the disease. However, emerging research suggests that uncoupling of proliferation and metastasis could redefine how we approach cancer treatment. At Mestastop, we are committed to understanding this distinction to pioneer groundbreaking strategies against cancer metastasis.

Understanding the Uncoupling Phenomenon

Traditionally, metastasis has been viewed as a byproduct of increased cell proliferation, implying that a tumor’s ability to grow correlates directly with its ability to spread. However, recent studies suggest that metastasis can occur independently of tumor proliferation. This means that even slow-growing tumors can exhibit high metastatic potential, emphasizing the need for a distinct approach to target metastasis rather than merely controlling tumor growth.

The Role of Mestastop in Metastasis Research

As the “Metastasis Specialists”, Mestastop envisions a future where multiple drugs will be available to prevent metastasis in an adjuvant setting. Our research solutions leverage technology-driven methodologies like ReSULT (Research Solutions for Understanding and Leveraging Tumor Metastasis) to dissect the mechanisms governing metastasis and develop targeted interventions.

Why Is Uncoupling Proliferation from Metastasis Important?

Improved Targeted Therapies: By understanding the genetic and molecular drivers of metastasis, independent of proliferation, we can develop treatments that specifically hinder cancer spread without affecting normal cell division.

Enhanced Early Diagnostics: Recognizing metastatic potential at an early stage can lead to better prognosis and treatment planning. Our ReSULT approach aids in early detection and assessment of metastasis risk.

New Therapeutic Avenues: Traditional therapies aim at shrinking tumors, often overlooking metastatic cells that have already disseminated. Uncoupling these processes allows us to develop drugs that prevent metastasis even when tumor proliferation is controlled.

The Mestastop Approach: Leveraging Technology for Better Outcomes

Mestastop integrates cutting-edge research and technology to decode the complexities of cancer metastasis. Our ReSULT methodology provides:

Comprehensive Data-Driven Insights: Mapping out metastatic patterns to identify key regulators and pathways.

Innovative Drug Discovery: Screening potential compounds that can inhibit metastasis.

Collaborative Research Models: Partnering with early diagnostic tools and therapeutic interventions to develop holistic treatment solutions.

A Future Without Metastatic Cancer

By focusing on uncoupling proliferation and metastasis, Mestastop is pioneering a paradigm shift in cancer treatment. Our commitment to fighting metastasis through scientific rigor and technological innovation places us at the forefront of cancer research. We aim to complement existing treatments with targeted anti-metastatic drugs, improving patient outcomes and revolutionizing cancer care.

The battle against cancer is far from over, but by addressing metastasis as a distinct and treatable entity, we move one step closer to a future where cancer no longer means an inevitable decline. With Mestastop leading the charge, the dream of preventing metastasis is within reach.

[mestastop]

Uncoupling of Proliferation and Metastasis: A Key to Cancer Treatment 

The uncoupling of proliferation and metastasis is a breakthrough concept in cancer research, offering new insights into how tumors spread and grow. Traditionally, cancer treatment has focused on targeting tumor growth or proliferation, but recent findings show that metastasis—the spread of cancer cells to other parts of the body—can occur independently from tumor proliferation. This has significant implications for how we understand and treat cancer. 

The uncoupling of proliferation and metastasis allows for a deeper understanding of the complexities of cancer progression. Tumors can grow in one location while simultaneously sending cells to distant organs, which can complicate treatment. This dual process means that targeting tumor growth alone may not be sufficient for preventing cancer's spread. Instead, focusing on the mechanisms that control both processes separately could lead to more effective therapies. 

Understanding this distinction is crucial because it opens the door for targeted therapies that focus on metastasis without necessarily affecting the tumor's ability to proliferate. Mestastop, a leading innovator in cancer treatment, provides solutions that aim to address the metastatic process without disrupting the proliferation of tumor cells. By targeting the specific pathways responsible for metastasis, Mestastop is working towards treatments that could prevent cancer from spreading, even in cases where tumor growth is not being effectively controlled. 

In conclusion, the uncoupling of proliferation and metastasis represents a pivotal shift in how cancer treatment may evolve in the future. With advancements from companies like this there is hope for therapies that target metastasis directly, offering a new strategy in the fight against cancer. This approach promises to improve outcomes for patients by focusing on the underlying causes of cancer spread, which are often overlooked in traditional treatments. 

[mestastop]

Metastasis drug discovery is crucial for developing targeted treatments to prevent cancer from spreading. We provide cutting-edge research and solutions in metastasis drug discovery, focusing on innovative approaches to identify and inhibit metastatic pathways. Their advanced technologies enable precise drug targeting, improving treatment outcomes and patient survival rates. By leveraging specialized research models and data-driven strategies, Mestastop accelerates the development of effective anti-metastatic therapies. With a commitment to innovation and scientific excellence,we plays a pivotal role in transforming cancer treatment and offering new hope for patients facing metastatic disease. 

[mestastop]

Understanding the Uncoupling of Proliferation and Metastasis in Cancer 

Uncoupling of proliferation and metastasis is a critical concept in cancer research, where tumor growth and metastatic spread are regulated independently. This phenomenon challenges traditional treatment strategies that primarily target tumor size, often neglecting metastatic potential.We provides cutting-edge solutions to study and manipulate this uncoupling of proliferation and metastasis, aiming to develop therapies that specifically inhibit metastasis without affecting normal cell proliferation. By identifying unique molecular pathways driving metastasis separately from tumor growth, researchers can create targeted interventions to improve patient survival rates. With advancements in cancer biology, understanding and controlling this process could revolutionize therapeutic approaches, leading to better clinical outcomes. Mestastop continues to pioneer research in this field, offering innovative tools and expertise to combat metastatic disease effectively. 

[mestastop]

The uncoupling of proliferation and metastasis is a groundbreaking concept in cancer therapy. This innovative approach focuses on decoupling the rapid growth of cancer cells from their ability to spread to other parts of the body. By targeting specific molecular pathways, researchers aim to inhibit metastasis without affecting the primary tumor's growth. Uncoupling of proliferation and metastasis represents a significant shift in cancer treatment strategy, offering the potential to improve patient outcomes and survival rates.  

[mestastop]

Understanding the Uncoupling of Proliferation and Metastasis 

The Uncoupling of Proliferation and Metastasis is a groundbreaking concept in cancer research that addresses how cancer cells can spread without uncontrolled growth. Mestastop provides innovative solutions to study and target this separation, helping in the development of therapies that specifically inhibit metastasis without affecting normal cell function. By understanding this mechanism, researchers can create more precise treatments to prevent cancer spread while minimizing side effects. Mestastop focuses on pioneering strategies to tackle metastasis as an independent factor, revolutionizing cancer treatment approaches. For more information, visit us at https://mestastop.com/, call us at +91 9177884450, or email us at bd@mestastop.com. 

[mestastop]

Uncoupling of Proliferation and Metastasis: A New Frontier in Cancer Research 

Cancer progression has long been associated with the simultaneous growth of tumors and their ability to spread to distant organs. However, recent research highlights a crucial aspect of cancer biology—the uncoupling of proliferation and metastasis. This concept challenges the traditional view that aggressive tumor growth always correlates with higher metastatic potential. Mestastop provides innovative solutions in this field, focusing on understanding and targeting metastasis independently of tumor proliferation. 

Understanding the Uncoupling of Proliferation and Metastasis 

Proliferation refers to the rapid multiplication of cancer cells within the primary tumor, whereas metastasis involves their migration and invasion into other parts of the body. Traditionally, both processes were believed to be interconnected, with fast-growing tumors being more likely to metastasize. However, studies now suggest that some cancer cells can maintain low proliferation rates while exhibiting high metastatic potential. This uncoupling of proliferation and metastasis is a critical finding because it explains why certain tumors remain small yet still lead to aggressive disease progression through distant organ colonization. 

Implications for Cancer Treatment 

Understanding this decoupling offers new therapeutic opportunities. Conventional cancer treatments like chemotherapy primarily target rapidly dividing cells, often overlooking metastatic cells that do not rely on high proliferation rates. By focusing on metastasis-specific pathways, researchers can develop therapies that prevent cancer spread even in cases where tumor growth is controlled. Mestastop specializes in such approaches, providing cutting-edge solutions to target metastasis independently of tumor size and growth rate. 

The Future of Cancer Research 

By shifting the focus from just tumor shrinkage to metastasis prevention, researchers can improve patient survival rates and reduce cancer recurrence. The uncoupling of proliferation and metastasis presents a paradigm shift in oncology, emphasizing the need for novel biomarkers and therapeutic strategies. As cancer research continues to evolve, targeting metastasis separately from tumor proliferation could redefine treatment outcomes. 

Mestastop is at the forefront of this innovative research, offering advanced solutions to tackle metastasis in a more effective manner. Stay informed about our latest developments by visiting https://mestastop.com/, calling us at 91+9177884450, or emailing us at bd@mestastop.com.